Microbiotica
- Biotech or pharma, therapeutic R&D
Leading precision microbiome medicines company. Microbiotca's platform identifies defined bacterial therapeutics targeting specific patient populations. Our lead assets in immuno-oncology and IBD are in clinical trials reading out in late 2025.
The compony was spun out of the Sanger Institute and has leading reference genome and informatics capabilities.
With lead assets in clinical trials in refractory, advanced melanoma patients in combination with Keytruda and IBD, Microbiotica has the potential to make amajor breakthrough in microbiome therapeutics in 2025.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}